The bill adds a new Part X to the Public Health Service Act to create a federal subscription-style contracting program that guarantees annual payments to sponsors of novel antimicrobials that meet specified public-health and innovation criteria. Contracts are available for drugs and biologics that address CDC-listed ‘urgent’ or ‘serious’ threats (or those designated via advisory consultation) and that meet an unmet medical need; an administrator-defined quantitative scoring system determines eligibility and payment levels.
Beyond the contracts, the bill funds expanded antimicrobial stewardship and surveillance through CDC grant programs and a pilot for outpatient stewardship, establishes a 15-member Critical Need Antimicrobial Advisory Group to advise scoring and eligibility, and appropriates $6 billion (FY2026, available until expended) to the program with up to 6.5% available for stewardship and surveillance activities. The structure is designed to de-link sponsor returns from sales volume to stimulate R&D, while imposing supply, reporting, stewardship, manufacturing, and environmental requirements on contract recipients.
At a Glance
What It Does
Creates a federal contracting authority to pay eligible antimicrobial sponsors annual fixed sums for up to 10 years (or until a generic/biosimilar enters the market), with payments set by a regulation-driven scoring system and adjusted downward by prior-year net U.S. revenue. Also funds CDC grants and an outpatient stewardship pilot and requires expanded resistance and use surveillance.
Who It Affects
Drug and biologic sponsors of new antimicrobials, FDA-approved or licensed products, hospitals and outpatient facilities (as grant recipients), diagnostic manufacturers (supply expectations), the CDC and HHS agencies responsible for scoring, surveillance, and contract administration, and taxpayers funding the appropriation.
Why It Matters
It operationalizes a subscription (delinked) payment model at scale — including concrete payment floors/ceilings and net-revenue offsets — that alters commercial incentives for antibiotic R&D, ties federal support to stewardship and supply commitments, and centralizes national resistance data collection.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill authorizes HHS to sign multi-year contracts with sponsors of antimicrobials that satisfy eligibility rules and score above a regulatory minimum. Sponsors must apply within two years of FDA approval or licensure; applications must include information needed for a numerical score but are not required to disclose pricing or R&D costs.
The Secretary has 90 days to review applications and will approve those that meet the minimum score and then calculate annual contract payments.
The scoring framework is to be fleshed out by regulation within 270 days and awards points across three weighted categories: (I) patient-care benefits (clinical outcomes, dosing, toxicity, administration route), (II) innovation characteristics (first-in-class status, novel targets or scaffolds, absence of previously approved active moieties), and (III) public-health value (no cross-resistance, U.S. manufacturing, stability, and reduced AMR burden). Regulations will set the minimum threshold and the weights used to convert criteria into a numeric score.Contract terms impose operational obligations: sponsors must ensure commercial availability and adequate manufacturing volume and supply for diagnostic manufacturers; publicly report resistance data and participate in stewardship communications and appropriate-use planning; prepare shortage mitigation plans if FDA identifies a shortage; follow environmental manufacturing best practices; and be subject to contract termination for market withdrawal, material noncompliance after notice, or failure to complete required postmarket studies.
Annual payments begin within 180 days of contract approval and must fall between $75 million and $300 million (CPI-adjusted), with each payment reduced by net U.S. revenue from prior-year sales (including discounts and rebates). The Secretary may keep revenue information confidential and limit use of disclosed data to payment calculation.The Advisory Group comprises 15 appointed members (infectious disease physicians, experts in AMR/economics/R&D, and patient advocates) plus a non-voting chair; appointees must have no compensation from antimicrobial commercial developers while serving.
The CDC receives new grant authorities to fund inpatient and outpatient stewardship (the outpatient pilot targets urgent-care and retail clinic settings), and the bill tasks CDC with intensifying antimicrobial use and resistance surveillance, integrating diagnostic data, and publishing regular public reports beginning two years after enactment. Finally, the bill authorizes $6 billion for the program (FY2026, available until expended) and designates the funds as emergency spending.
The Five Things You Need to Know
The program authorizes annual subscription payments per contract of not less than $75 million and not more than $300 million (CPI-adjusted), with payments reduced by prior-year net U.S. revenue.
A product must be FDA-approved or licensed and address a CDC ‘urgent’ or ‘serious’ threat (or be designated via the Advisory Group) and satisfy an unmet medical need to qualify.
The Secretary must promulgate a quantitative scoring methodology within 270 days and complete application reviews within 90 days of receipt.
Contract obligations include ensuring U.S. commercial availability, supplying diagnostic manufacturers, public resistance reporting, stewardship education materials, environmental manufacturing standards, and shortage mitigation plans.
The bill appropriates $6 billion (FY2026, available until expended) and allows up to 6.5% of that sum to be used for CDC stewardship and surveillance activities.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Federal subscription contracts for eligible antimicrobials
This section creates HHS authority to enter into contracts with sponsors of eligible antimicrobials and sets the application, review, and contracting framework. It defines timing (applications within two years of approval/licensure), a 90-day review clock, and directs HHS to calculate annual payments after approval. Practically, it centralizes a single federal gatekeeper for subscription awards and builds in an administrative cadence for approvals and payments.
Regulatory scoring methodology and eligibility threshold
HHS must publish regulations establishing a quantitative, weighted scoring system in consultation with specified HHS components and the Advisory Group. The score uses three categories—patient benefit, innovation, and system/public-health value—with weights to be determined by rule. The scoring design will decide which products clear the minimum threshold and therefore who receives contracts; choices about weights and metrics will materially affect which therapeutic profiles the program prioritizes.
Sponsor obligations, payment calculus, contract length, and termination
Contracts require sponsors to maintain U.S. commercial supply (including for diagnostic manufacturers), run stewardship education and reporting, follow environmental manufacturing standards, and prepare shortage response plans. Payments begin within 180 days, are set between statutory floors and ceilings, and are adjusted down by prior-year net U.S. revenue (including discounts/rebates). Contracts last up to 10 years or until an approved generic/biosimilar is marketed; HHS can terminate payments for withdrawal, material noncompliance after notice, or failure to complete required postmarket studies.
Critical Need Antimicrobial Advisory Group to advise on eligibility and scoring
HHS must form a 15-member Advisory Group composed of infectious disease physicians, AMR/R&D/economics experts, and patient advocates plus a non-voting chair. Appointees may not receive compensation from antimicrobial commercial developers while serving, and FACA generally applies except that the committee won’t automatically terminate under the usual statute-driven sunset. The group is the statutory consultative body for scoring and pathogen designation decisions.
CDC grant programs, outpatient stewardship pilot, and expanded surveillance
CDC gets authority to run grants for hospitals and other facilities to build antibiotic stewardship programs, prioritizing facilities without existing programs, rural and critical access hospitals, tribal-serving hospitals, and safety-net hospitals. The bill also creates an outpatient stewardship pilot aimed at urgent-care and retail clinics, requires adherence to recognized stewardship standards, and directs CDC to scale NHSN and other systems for use/resistance and diagnostics data collection, with public reporting starting two years after enactment.
Key definitional boundaries and funding
Definitions clarify which products count as antimicrobial drugs and what constitutes a contract or contract antimicrobial. The bill authorizes $6 billion for FY2026 (available until expended), permits up to 6.5% of that total to be used for stewardship and surveillance, and designates funding as emergency spending—an explicit budgetary signal to finance the program without standard offsets.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with multi-drug-resistant infections — the program targets drugs that improve clinical outcomes, reduce toxicity, or enable oral administration, increasing the chance new effective therapies reach clinical use.
- Public health agencies and hospitals — expanded CDC surveillance and grant-funded stewardship capacity improve system readiness and data for outbreak detection and AMR trend analysis.
- Diagnostic manufacturers — sponsors are contractually required to ensure sufficient supply for antimicrobial susceptibility testing, supporting diagnostic availability and integration into stewardship.
- Drug developers of truly novel antimicrobials — the de-linked revenue model lowers market-risk by guaranteeing predictable cashflows that can justify costly R&D for first-in-class products.
- Domestic manufacturers and supply-chain actors — incentives favor U.S. manufacturing capability and supply reliability, potentially strengthening domestic production capacity.
Who Bears the Cost
- U.S. taxpayers and federal budget — the program relies on a $6 billion appropriation (FY2026) and ongoing fiscal exposure for multi-year contracts.
- HHS/CDC and interagency implementers — building scoring regulations, running application reviews, administering complex payments, and expanding surveillance will require agency staffing and systems integration.
- Sponsor companies that accept contracts — they must meet non-sales obligations (supply, stewardship, environmental standards) that add manufacturing and reporting costs; failure risks payment termination.
- Smaller outpatient providers and urgent-care/retail clinics — while eligible for pilot grants, they will face implementation and reporting requirements to meet stewardship standards if they participate.
- Payers and CMS — CMS consultation is required for payment calculation rules and may need to integrate program outputs into reimbursement or quality frameworks.
Key Issues
The Core Tension
The central dilemma is between incentivizing antibiotic innovation by removing reliance on volume-based sales (which promotes development of drugs used sparingly) and the fiscal and allocative risks of committing large public sums with imperfect ability to predict clinical value or to ensure that payments reward truly novel, population-level benefit rather than incremental gains.
The bill deliberately de-links sponsor returns from unit sales by guaranteeing fixed annual payments, then offsets those payments by net U.S. revenue. That reduces commercial pricing risk but introduces complex measurement questions: how to define net revenue, which discounts count, and how to audit sponsor disclosures while preserving confidentiality.
The statute permits HHS to keep revenue data confidential and limits its use to payment calculation, which protects proprietary information but reduces transparency for external stakeholders assessing program value. Implementation will require robust, secure data interfaces between sponsors, HHS, and possibly CMS to calculate offsets accurately.
Operationalizing the scoring system presents another practical challenge. Regulators must convert qualitative clinical and public-health attributes into a quantitative, weighted numeric score that determines access to sizable public funds.
Weighting choices (e.g., prioritizing first-in-class innovation vs. system-level impact like U.S. manufacturing) will materially shape the pipeline that receives support and may advantage certain modalities over others. The CDC-facing surveillance and stewardship provisions expand data collection across diverse settings and call for near-real-time availability, but achieving comparable, high-quality datasets across hospitals, outpatient clinics, pharmacies, and labs requires substantial technical harmonization, legal data-sharing arrangements, and funding beyond initial appropriations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.